aviptadil: Clinical Trials

5 trials of aviptadil, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated, 1 withdrawn. 5 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 3, Terminated 1, Withdrawn 1
Phase 22Completed 1, Terminated 1

Follow aviptadil: new trials by email Literature Review of aviptadil trials Research Report on aviptadil

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID
Phase 3WithdrawnAPR Applied Pharma Research s.a.2021-12-152026-05-14
Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
Aviptadil, Aviptadil Placebo, Corticosteroid - Covid19
Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)4712021-04-202025-10-09
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
Remdesivir, Remdesivir Placebo, Aviptadil - Covid19
Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)4732021-04-202025-10-24
Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19
ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID
Phase 2 / Phase 3TerminatedAPR Applied Pharma Research s.a.1442021-02-152023-02-03
Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
Aviptadil by intravenous infusion + standard of care, Normal Saline Infusion + standard of care - Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Phase 2 / Phase 3CompletedAPR Applied Pharma Research s.a.2032020-05-152023-07-24

Conditions studied

Acute Lung Injury (3)  ·  COVID-19 (3)  ·  Coronavirus Infections (3)  ·  Respiratory Distress Syndrome (3)  ·  Coronaviridae Infections (2)  ·  Dyspnea (2)  ·  Nidovirales Infections (2)  ·  RNA Virus Infections (2)  ·  Severe Acute Respiratory Syndrome (2)  ·  Virus Diseases (2)  ·  Respiratory Insufficiency (1)

Sponsors

APR Applied Pharma Research s.a. (3)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (2)

Countries

United States (4)

Top investigators

Jonathan C Javitt, MD, MPH (3)  ·  Prof. James Neaton (2)  ·  Samuel Brown, MD (2)

Results publications

PMID 34825704, PMID 36044317, PMID 36695483, PMID 37348524